Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Antitumor Cannabinoid Chemotypes: Structural Insights.

Morales P, Jagerovic N.

Front Pharmacol. 2019 May 31;10:621. doi: 10.3389/fphar.2019.00621. eCollection 2019.

2.

Increased expression of cannabinoid CB2 and serotonin 5-HT1A heteroreceptor complexes in a model of newborn hypoxic-ischemic brain damage.

Franco R, Villa M, Morales P, Reyes-Resina I, Gutiérrez-Rodríguez A, Jiménez J, Jagerovic N, Martínez-Orgado J, Navarro G.

Neuropharmacology. 2019 Jul 1;152:58-66. doi: 10.1016/j.neuropharm.2019.02.004. Epub 2019 Feb 7.

PMID:
30738036
3.

Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB1-CB2 heteroreceptor complexes.

Navarro G, Reyes-Resina I, Rivas-Santisteban R, Sánchez de Medina V, Morales P, Casano S, Ferreiro-Vera C, Lillo A, Aguinaga D, Jagerovic N, Nadal X, Franco R.

Biochem Pharmacol. 2018 Nov;157:148-158. doi: 10.1016/j.bcp.2018.08.046. Epub 2018 Sep 6.

PMID:
30194918
4.

Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism.

Morales P, Goya P, Jagerovic N.

Biochem Pharmacol. 2018 Nov;157:8-17. doi: 10.1016/j.bcp.2018.07.031. Epub 2018 Jul 26. Review.

PMID:
30055149
5.

New Methods for the Synthesis of Cannabidiol Derivatives.

Lago-Fernandez A, Redondo V, Hernandez-Folgado L, Figuerola-Asencio L, Jagerovic N.

Methods Enzymol. 2017;593:237-257. doi: 10.1016/bs.mie.2017.05.006. Epub 2017 Jul 3. Review.

PMID:
28750806
6.

An Overview on Medicinal Chemistry of Synthetic and Natural Derivatives of Cannabidiol.

Morales P, Reggio PH, Jagerovic N.

Front Pharmacol. 2017 Jun 28;8:422. doi: 10.3389/fphar.2017.00422. eCollection 2017. Review.

7.

New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.

Ragusa G, Gómez-Cañas M, Morales P, Rodríguez-Cueto C, Pazos MR, Asproni B, Cichero E, Fossa P, Pinna GA, Jagerovic N, Fernández-Ruiz J, Murineddu G.

Eur J Med Chem. 2017 Feb 15;127:398-412. doi: 10.1016/j.ejmech.2017.01.002. Epub 2017 Jan 4.

PMID:
28088085
8.

Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders.

Navarro G, Morales P, Rodríguez-Cueto C, Fernández-Ruiz J, Jagerovic N, Franco R.

Front Neurosci. 2016 Sep 13;10:406. doi: 10.3389/fnins.2016.00406. eCollection 2016. Review.

9.

Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.

Morales P, Gómez-Cañas M, Navarro G, Hurst DP, Carrillo-Salinas FJ, Lagartera L, Pazos R, Goya P, Reggio PH, Guaza C, Franco R, Fernández-Ruiz J, Jagerovic N.

J Med Chem. 2016 Jul 28;59(14):6753-6771. doi: 10.1021/acs.jmedchem.6b00397. Epub 2016 Jul 6.

10.

A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives.

Lazzari P, Distinto R, Manca I, Baillie G, Murineddu G, Pira M, Falzoi M, Sani M, Morales P, Ross R, Zanda M, Jagerovic N, Pinna GA.

Eur J Med Chem. 2016 Oct 4;121:194-208. doi: 10.1016/j.ejmech.2016.05.011. Epub 2016 May 6.

PMID:
27240274
11.

Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.

Morales P, Hernandez-Folgado L, Goya P, Jagerovic N.

Expert Opin Ther Pat. 2016 Jul;26(7):843-56. doi: 10.1080/13543776.2016.1193157. Epub 2016 Jun 7. Review.

PMID:
27215781
12.

Benzyl-1,2,4-triazoles as CB 1 Cannabinoid Receptor Ligands: Preparation and In Vitro Pharmacological Evaluation.

Hernandez-Folgado L, Decara J, Rodríguez de Fonseca F, Goya P, Jagerovic N.

Int J Med Chem. 2016;2016:1257098. doi: 10.1155/2016/1257098. Epub 2016 Mar 31.

13.

Advances Towards The Discovery of GPR55 Ligands.

Morales P, Jagerovic N.

Curr Med Chem. 2016;23(20):2087-100. Review.

PMID:
27109575
14.

Antichagasic and trichomonacidal activity of 1-substituted 2-benzyl-5-nitroindazolin-3-ones and 3-alkoxy-2-benzyl-5-nitro-2H-indazoles.

Fonseca-Berzal C, Ibáñez-Escribano A, Reviriego F, Cumella J, Morales P, Jagerovic N, Nogal-Ruiz JJ, Escario JA, da Silva PB, Soeiro Mde N, Gómez-Barrio A, Arán VJ.

Eur J Med Chem. 2016 Jun 10;115:295-310. doi: 10.1016/j.ejmech.2016.03.036. Epub 2016 Mar 17.

PMID:
27017556
15.

Identification of Novel GPR55 Modulators Using Cell-Impedance-Based Label-Free Technology.

Morales P, Whyte LS, Chicharro R, Gómez-Cañas M, Pazos MR, Goya P, Irving AJ, Fernández-Ruiz J, Ross RA, Jagerovic N.

J Med Chem. 2016 Mar 10;59(5):1840-53. doi: 10.1021/acs.jmedchem.5b01331. Epub 2016 Feb 5.

PMID:
26789378
16.

Allosteric Modulators of the CB1 Cannabinoid Receptor: A Structural Update Review.

Morales P, Goya P, Jagerovic N, Hernandez-Folgado L.

Cannabis Cannabinoid Res. 2016 Jan 1;1(1):22-30. doi: 10.1089/can.2015.0005. eCollection 2016. Review.

17.

Synthesis, pharmacological evaluation and docking studies of pyrrole structure-based CB2 receptor antagonists.

Ragusa G, Gómez-Cañas M, Morales P, Hurst DP, Deligia F, Pazos R, Pinna GA, Fernández-Ruiz J, Goya P, Reggio PH, Jagerovic N, García-Arencibia M, Murineddu G.

Eur J Med Chem. 2015 Aug 28;101:651-67. doi: 10.1016/j.ejmech.2015.06.057. Epub 2015 Jul 15.

PMID:
26209834
18.

Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.

Morales P, Blasco-Benito S, Andradas C, Gómez-Cañas M, Flores JM, Goya P, Fernández-Ruiz J, Sánchez C, Jagerovic N.

J Med Chem. 2015 Mar 12;58(5):2256-64. doi: 10.1021/acs.jmedchem.5b00078. Epub 2015 Feb 20.

PMID:
25671648
19.

Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results.

Fernández-Fernández C, Callado LF, Girón R, Sánchez E, Erdozain AM, López-Moreno JA, Morales P, Rodríguez de Fonseca F, Fernández-Ruiz J, Goya P, Meana JJ, Martín MI, Jagerovic N.

Drug Des Devel Ther. 2014 Feb 20;8:263-77. doi: 10.2147/DDDT.S55045. eCollection 2014.

20.

Synthetic cannabinoid quinones: preparation, in vitro antiproliferative effects and in vivo prostate antitumor activity.

Morales P, Vara D, Goméz-Cañas M, Zúñiga MC, Olea-Azar C, Goya P, Fernández-Ruiz J, Díaz-Laviada I, Jagerovic N.

Eur J Med Chem. 2013;70:111-9. doi: 10.1016/j.ejmech.2013.09.043. Epub 2013 Oct 2.

PMID:
24141201

Supplemental Content

Loading ...
Support Center